Therapeutic Area

Antihypertensive

Therapeutic area intelligence for Antihypertensive with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 3

Companies

Lupin Ltd. →

Micro Labs →

Strides Pharma →

Assets

FDA →

Losartan Potassium →

Pediatric Patients →

Recent signals(4)

RegulatoryJune 21, 2026

FDA Grants AP Status for Losartan Potassium ANDA090382 by Strides Pharma

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Losartan Potassium submitted by Strides Pharma.

StrategyJune 21, 2026

Lupin's ANDA078232 for Losartan Potassium Receives AP Status from FDA

Lupin Ltd. has received an Abbreviated New Drug Application (ANDA) approval status for Losartan Potassium.

ClinicalJune 20, 2026

Limited FDA-approved Antihypertensive Therapies for Pediatric Patients Highlighted

There is a significant unmet medical need for antihypertensive therapies in pediatric patients, especially those under six years old.

RegulatoryJune 7, 2026

FDA Approval Status Update for Losartan Potassium by Micro Labs

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Losartan Potassium submitted by Micro Labs.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.